As of Q3'25, UnitedHealth Group (UNH) reported SG&A Expenses of $15.2B USD, while R&D Expenses remained at $0 USD. This marks the highest SG&A expense recorded in the period covered, with no R&D spending reported throughout. From Q1'23 to Q3'25, SG&A Expenses have shown moderate fluctuations, generally ranging between $12.5B and $14.1B USD before a notable increase to $15.2B USD in Q3'25. There is a consistent absence of R&D Expenses across all quarters, indicating a lack of investment in research and development during this timeframe. The overall trend suggests stable operating expenses with a recent upward inflection in SG&A costs.